Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 7/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.38 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.37 |
| ▸ | GABRE | P78334 | 2/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.37 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.37 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.37 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26429735 | 1.00 | NAAA (0.42) | NAAAS1PR1S1PR3GABRPGABRD | |
| SCHEMBL26429731 | 0.94 | S1PR1 (0.38) | NAAAS1PR1S1PR3GABRPGABRD | |
| SCHEMBL34463948 | 0.94 | S1PR1 (0.38) | NAAAS1PR1S1PR3GABRPGABRD | |
| SCHEMBL30345627 | 0.90 | PPARD (0.37) | NAAAS1PR1S1PR3MGLL | |
| SCHEMBL26429712 | 0.90 | PPARD (0.37) | NAAAS1PR1S1PR3MGLL | |
| SCHEMBL23744631 | 0.89 | NAAA (0.46) | NAAAKCNH2MCHR1CHRM4 | |
| SCHEMBL30345506 | 0.86 | NAAA (0.45) | NAAAS1PR1S1PR3GABRPGABRD | |
| SCHEMBL26429732 | 0.86 | NAAA (0.45) | NAAAS1PR1S1PR3GABRPGABRD | |
| SCHEMBL30345664 | 0.86 | NAAA (0.45) | NAAAS1PR1S1PR3GABRPGABRD | |
| SCHEMBL26429733 | 0.86 | NAAA (0.45) | NAAAS1PR1S1PR3GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | claimed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | NAAA 1419/4885S1PR1 427/4885S1PR3 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.